ENTRESTO (sacubitril and valsartan)

HUMAN PRESCRIPTION DRUGORALAngiotensin 2 Receptor Blocker [EPC]

At a glance (from approved patient reviews)

Effectiveness

—

Would recommend

—

Used for

1 INDICATIONS AND USAGE ENTRESTO is a combination of sacubitril, a neprilisin inhibitor, and valsartan, an angiotensin II receptor blocker, and is indicated: to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are mo

Recent patient reviews

No approved patient reviews yet.

Write a Review

Share your experience with ENTRESTO. Reviews are held for moderation before publication.

Basic drug information

Brand: ENTRESTO

Generic: sacubitril and valsartan

Manufacturer: Novartis Pharmaceuticals Corporation

FDA application: NDA207620

Government sourced

Label facts are imported from openFDA/DailyMed. Patient reviews are clearly separated and moderated.

Last sourced from government data: 8/14/2026, 6:43:39 PM

FDA label warnings

WARNING: FETAL TOXICITY When pregnancy is detected, discontinue ENTRESTO as soon as possible (5.1) Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus (5.1) WARNING: FETAL TOXICITY See full prescribing information for complete boxed warning. Whe

FAERS reported reactions

hypotension11,577

death9,146

dyspnoea8,999

dizziness8,718

fatigue8,713

cough7,867

wrong technique in product usage process7,322

weight decreased5,209

FAERS reports do not establish that a drug caused an event. Counts are unadjusted public reports.